Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Netrin-1 is a dependence receptor ligand participating in the pathology of several cancer types. It is up-regulated in chronic liver diseases, cirrhosis and HCC. We hypothesize that netrin-1 may play a detrimental role in HCC. The goal of this project is to characterize netrin-1 signals in HCC samples with ad hoc controls, to investigate the benefit of capturing netrin-1 in preclinical models of HCC and to try to define patients groups the most likely to benefit from this targeting approach in the clinic.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tumors (T) samples of various etiologies (HBV, HCV, NASH, alcool) | The combination of the Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool) |
| |
| Non Tumors (NT) samples of various etiologies (HBV, HCV, NASH, alcool) | The combination of the Non Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Quantification of netrin-1 signals by antibody-based approaches | Procedure | Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion. |
| Measure | Description | Time Frame |
|---|---|---|
| Netrin-1 expression patterns in HCC samples | Netrin-1 expression levels will be quantified by immunoblotting with ad hoc internal standards. Positivity threshold by IHC will be evaluated using ad hoc positive and negative control tissues. The densitometry approach will be used. | Outcome measure is to be performed after surgery of the tumors (at least 1 year later). It has no impact on the patient's care. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
- absence of informed consent
Not provided
Not provided
Both men and women, between 18 and 85 years of age, suffering from Hepatocellular Carcinoma.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Fabien ZOULIM, Pr | Contact | 4 26 10 93 55 | +33 | fabien.zoulim@chu-lyon.fr |
| Romain PARENT | Contact | 4 72 68 19 70 | +33 | romain.parent@inserm.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hepatogastroenterology service of the Croix-Rousse Hospital | Recruiting | Lyon | 69004 | France |
Not provided
Not provided
Not provided
Not provided